Rifaximin 550 MG: Oral Rifaximin 550mg twice daily from the start of pelvic radiotherapy, with or without chemotherapy, as a preventive measure, and continuing every day until the end of the treatment up to 5 to seven weeks.
Standard Care Chemoradiation: Patients will receive standard chemotherapy and/or radiation
Study summary
Preclinical data indicate that rifaximin could be repurposed as a novel strategy for preventing and reducing the severity of gastrointestinal damage, particularly diarrhea, that results from pelvic irradiation. So, The aim of the work is to investigate the impact of Rifaximin on the incidence and severity of radiotherapy-induced diarrhea in cancer patients undergoing pelvic irradiation with or without chemotherapy.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Individuals who are 18 years of age or older and have been diagnosed with non metastatic pelvic cancers.
* Patients who are undergoing curative intent radiotherapy with or without chemotherapy treatment.
Exclusion Criteria:
* Patients who have a record of intestinal resection in their medical history.
* Patients with a medical background of irritable bowel syndrome.
* Patients with a history of inflammatory bowel disease.
* Patients who regularly take anti-diarrheal medications before commencing radiotherapy.
* Patients experiencing diarrhea at the outset of the study.
* Patients with compromised immune systems, such as those who are HIV positive or using immunosuppressive medications.
* Pregnant or lactating woman.
* Patients allergic to rifamycin.
Primary outcome measure(s)
The difference in the incidence and severity of radiotherapy induced diarrhea grade 2 or more according to Common Terminology Criteria for Adverse Events (CTCAE)in cancer patients undergo pelvic irradiation. — 12 months
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.